Sickle Cell Trait and Diabetes Tests: What Every Healthcare Provider Should Know

Details

• Corporate Authors:
  National Center on Birth Defects and Developmental Disabilities (Centers for Disease Control and Prevention) ; American Society of Hematology. ; Sickle Cell Disease Association of America.
• Description:
  According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the hemoglobin A1C assay may be unreliable for diagnosing and monitoring diabetes and prediabetes in individuals with sickle cell trait (SCT) or other hemoglobinopathies. In order to provide the best possible care for your patients, it is important to determine their SCT status and know whether the A1C test you normally use should be replaced or supplemented with a different test.
  
  CS258998A
  
  Publication date from document properties.
  
  
• Subjects:
  Anemia, Sickle Cell Anemia, Sickle Cell/diagnosis Anemia, Sickle Cell/genetics Hemoglobin, Sickle/analysis Hemoglobin A, Glycosylated/analysis Mass Screening/analysis
• Series:
  Sickle Cell Trait Toolkit
• Document Type:
  Text
• Genre:
  Fact Sheet
• Pages in Document:
  1 unnumbered page
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha-512:b3ddbe47a50fc2bfdff15c447aa0b06e15cc3c9436505aa7c345c5cfc5d2b7348e56b05b8c5de07bd21c22045665191250deaba6c723a8d8556b2b65e977d6dc
• Download URL:
  https://stacks.cdc.gov/view/cdc/33971/cdc_33971_DS1.pdf
• File Type:
  [PDF - 385.42 KB ]